

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE

02 FEB 14 PM 5:57

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name GlaxoSmithKline			
2. Address <input type="checkbox"/> Check if different than previously reported 1500 K Street, NW #650			
3. Principal Place of Business (if different from line 2) City: Washington State/Zip (or Country) DC 20005			
4. Contact Name Janie A. Kinney	Telephone (202) 715-1000	E-mail (optional)	5. Senate ID# 16293-12
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID# 31461000

TYPE OF REPORT 8. Year 2001 Midyear (January 1-June 30) Year End (July 1-December 31)


9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇒ Termination Date _____ 11. No Lobbying Activity

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organization
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this report were:
Less than \$10,000 <input type="checkbox"/>	Less than \$10,000 <input type="checkbox"/>
\$10,000 or more <input type="checkbox"/> ⇒ \$ _____ Expenses (nearest \$20,000)	\$10,000 or more <input checked="" type="checkbox"/> ⇒ \$ <u>2,260,000.00</u> Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of
	<input checked="" type="checkbox"/> Method A. Reporting amounts used LDA definition
	<input type="checkbox"/> Method B. Reporting amounts under section 6011 of the Internal Revenue Code
	<input type="checkbox"/> Method C. Reporting amounts under section 162 of the Internal Revenue Code

Signature



Date

February 14, 2002

Printed Name and Title

Sarah J. Walsh, Director Federal Government Relations



Registrant Name GlaxoSmithKline Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which t engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each coc** information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific lobbying issues

S. 754 The Drug Competition Act of 2001
S. 812 Greater Access to Affordable Pharmaceuticals Act
H.R. 1862 Greater Access to Affordable Pharmaceuticals Act
H.R. 741 Madrid Protocol Implementation

17. House(s) of congress and Federal agencies contacted Check if None

U.S. House Of Representatives
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Janie A. Kinney	
Sarah J. Walsh	
Patrick McLain	
William Schuyler	
Elizabeth York	
Kimberly A. Williams	
Mary Frances Daly	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date February 14, 2002

Printed Name and Title Sarah J. Walsh, Director Federal Government Relations



Registrant Name GlaxoSmithKline Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which t engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each coc** information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

- S. 358 Medicare Prescription Drug & Modernization Act of 2001
- H.R. 1400 Prescription Drug Fairness for Seniors Act of 2001
- H.R. 1229 Medicare, Medicaid and MCH Smoking Cessation Promotion Act
- S. 854 Medicare, Medicaid and MCH Smoking Cessation Promotion Act

17. House(s) of congress and Federal agencies contacted Check if None

U.S. House Of Representatives
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Janie A. Kinney	
Sarah J. Walsh	
Patrick McLain	
William Schuyler	
Elizabeth York	
Kimberly A. Williams	
Mary Frances Daly	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date February 14, 2002

Printed Name and Title Sarah J. Walsh, Director Federal Government Relations



Registrant Name GlaxoSmithKline Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific lobbying issues

H.R. 2500 Commerce, Justice, State Appropriations Act of 2002
H.R. 2116 Supplemental Appropriations Act
H.R. 1504 Vaccines for the New Millenium Act
S. 895 Vaccines for the new Millenium Act
H.R. 580 Comprehensive Insurance Coverage of Childhood Immunization
H.R. 3338 DoD Appropriations Act of 2002
H.R. 3061 Department of Labor, Health, & Human Services & Education, Related Agencies Appropriations Act
S. 1536 Department of Labor, Health, & Human Services & Education, Related Agencies Appropriations Act

17. House(s) of congress and Federal agencies contacted Check if None

U.S. House Of Representatives
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Janie A. Kinney	
Sarah J. Walsh	
Patrick McLain	
William Schuyler	
Elizabeth York	
Kimberly A. Williams	
Mary Frances Daly	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date February 14, 2002

Printed Name and Title Sarah J. Walsh, Director Federal Government Relations



Registrant Name GlaxoSmithKline Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which t engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each co** information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

- S.838 The Best Pharmaceuticals for Children Act
- S. 2330 Agriculture Appropriations Act of 2002
- S. 1731 Puppy Protection Act
- H. Con. Res. 197 Chronic Obstructive Pulmonary Disease Awareness Month
- H.R. 2887 Best Pharmaceuticals for Children Act

17. House(s) of congress and Federal agencies contacted Check if None

U.S. House Of Representatives
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Janie A. Kinney	
Sarah J. Walsh	
Patrick McLain	
William Schuyler	
Elizabeth York	
Kimberly A. Williams	
Mary Frances Daly	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date February 14, 2002

Printed Name and Title Sarah J. Walsh, Director Federal Government Relations



Registrant Name GlaxoSmithKline Client Name Self

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different from line 20)

City _____ State/Zip (or Country) _____

22. New general description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issues previously reported that **no longer** pertain

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Name	Address	Principal Place of B (city and state or co
NONE		


26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

Name	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities	(pe
NONE				

28. Name of each previously reported foreign entity that **no longer** owns, **or** controls, **or** is affiliated with the registrant, client or affiliated organization

Signature  Date February 14, 2002
Printed Name and Title Sarah J. Walsh, Director Federal Government Relations

